Prestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025. In the quarter to June 2026, revenue grew 6.48%, EPS fell 36.5%, free cash flow fell 14.2% and total debt rose 100.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow PBH
Prestige Consumer Healthcare Inc. (PBH) EV/Sales
As of 16 October 2026, Prestige Consumer Healthcare Inc. (PBH) trades at a EV/Sales of 3.9×. Over the past ten years it has ranged from 2.9× (June 2026) to 5.9× (April 2017); the current reading is higher than 45% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 3.5× | (22.99%) |
| FY2025 | 4.6× | 10.41% |
| FY2024 | 4.1× | 5.48% |
| FY2023 | 3.9× | 3.38% |
| FY2022 | 3.8× | (2.61%) |
| FY2021 | 3.9× | 6.97% |
| FY2020 | 3.6× | 7.45% |
| FY2019 | 3.4× | (5.15%) |
| FY2018 | 3.6× | (38.23%) |
| FY2017 | 5.8× | 5.47% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.8× | 7.78% |
| Mar 2026 | 3.5× | (1.80%) |
| Dec 2025 | 3.6× | 0.40% |
| Sep 2025 | 3.6× | (17.31%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −0.1× |
| PRGO Perrigo Company plc compare | 1.3× |
| ANIP ANI Pharmaceuticals, Inc. compare | 1.8× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.6× |
| SUPN Supernus Pharmaceuticals, Inc. compare | 2.8× |
| PBH Prestige Consumer Healthcare Inc. | 3.9× |
| XERS Xeris Biopharma Holdings, Inc. compare | 5.7× |
| LQDA Liquidia Corporation compare | 6.5× |
| ALVO Alvotech compare | 9.0× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)